"While an HIV vaccine remains elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk," said Dr Tedros ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

WHO releases new guidelines recommending injectable lenacapavir for HIV prevention: Geneva Wednesday, July 16, 2025, 10:00 Hrs [IST] The World Health Organization (WHO) released n ...

South Asia has achieved its highest-ever immunization coverage for children, with notable progress in India and Nepal, ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

A company was ordered to pay hundreds of thousands of dollars to D.C. to settle claims that it engaged in an illegal kickback scheme.

Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts ...

MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.

Kenya has been picked among nine countries for the trials of the new injectable HIV prevention drug that has been rolled out by the World Health Organisation.